Trimel Pharmaceuticals Corp  

(Public, CVE:JV.P)   Watch this stock  
Find more results for Gregory P Hawkins´┐Ż
0.120
Delayed:   2:14PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.21
Open     -
Vol / Avg. 0.00/19,467.00
Mkt cap 1.20M
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -
Nov 4, 2015
Q3 2015 Trimel Pharmaceuticals Corp Earnings Release (Estimated) Add to calendar
Aug 6, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Call
Aug 5, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Release
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -59.40% -525.04%
Operating margin -20.26% -502.34%
EBITD margin - -407.84%
Return on average assets -9.68% -43.52%
Return on average equity -61.05% -150.79%
Employees 19 -
CDP Score - -

Address

2488 Dunwin Dr
MISSISSAUGA, ON L5L 1J9
Canada
+1-416-6790771 (Phone)

Website links

Description

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical Company. The Company is engaged in the sale, distribution and development of products with a focus in men's health and women's health. The Company's products include Natesto, Estrace and Tefina. Natesto is a bioadhesive intranasal gel formulation of testosterone and is indicated for male hypogonadism. Natesto is available in United States. Estrace is an oral 17-beta estradiol tablet, which provides symptomatic relief of menopausal symptoms and also contributes to the prevention of osteoporosis in estrogen-deficiency. Tefina is an intranasal, low-dose gel formulation of testosterone and is indicated for female orgasmic disorder. Tefina has completed its Phase II clinical trials. The Company's holds a license for the development and marketing rights of its products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a unit-dose dry powder inhaler/nasal dispersion system, TriVair.

Officers and directors

Ian O. Ihnatowycz Independent Chairman of the Board
Age: 61
Tom Rossi President, Chief Executive Officer, Director
Michael Bumby Chief Financial Officer
Age: 50
Matthew Hawkins Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson Vice President - Scientific Affairs
Rolf K. Reininghaus Executive Director, Director
Stephen Robert Gregory Lead Independent Director
Norma Beauchamp Director
Matthew J. Pfeffer CPA Independent Director
Age: 57
Jeffrey D. Sherman Independent Director